Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced significant interest from orthopedic surgeons, physicians, and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held October 8-10 in Porto, Portugal. The discussions centered on GelrinC®, the company's CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage in a single procedure lasting approximately 10 minutes. This strong surgeon engagement is important because it signals growing clinical acceptance of a novel treatment that could address a major unmet need in orthopedics.
GelrinC's potential is underscored by clinical data: in a Phase II study, it demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score (KOOS) compared with historical microfracture controls at two years, with MRI analyses showing durable, native-like cartilage regeneration. These results are particularly significant because microfracture, the current standard of care, often yields inconsistent and temporary relief. If GelrinC's benefits are confirmed in larger trials, it could become a preferred first-line treatment for cartilage defects, reducing the need for more invasive procedures and delaying or preventing knee replacement surgeries.
The interest from surgeons at the ICRS Summit is a critical step toward broader clinical adoption. Regentis is leveraging this momentum by expanding its European Centers of Excellence, which will serve as training and referral hubs for the procedure. In parallel, the company is advancing its ongoing U.S. Food and Drug Administration pivotal trial, a necessary milestone for market entry in the United States. The U.S. market represents approximately 470,000 cartilage knee repair cases annually, and currently no off-the-shelf treatment is available, according to the company. GelrinC's off-the-shelf, cell-free design could streamline surgical workflows and improve patient access.
For investors, the news highlights Regentis' progress in a high-value regenerative medicine niche. The company's Gelrin platform technology, based on synchronized, degradable hydrogel implants, may have applications beyond cartilage, potentially expanding its long-term market opportunity. As Regentis works to translate physician interest into adoption, successful execution of its European expansion and U.S. trial will be key catalysts. The full press release can be viewed at https://ibn.fm/hcEu4. For more information about Regentis Biomaterials (NYSE American: RGNT), visit Regentis Biomaterials (NYSE American: RGNT).
The announcement was disseminated through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers, among other corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
